WLK — Westlake
TL;DR
Westlake is a vertically integrated chemicals and building products company with two distinct segments: commodity chemicals (PVC, chlor-alkali, polyethylene) and building products (pipes, fittings, windows, siding). The building products business provides earnings resilience that the pure-play petchem names lack. After a strong YTD rally, BofA rates WLK Neutral at 119 PO — the stock screens close to fair value, with limited upside and a more balanced risk-reward than DOW or LYB.1
Business
Westlake operates two segments: (1) Vinyls — chlor-alkali, PVC, PE, and compounds, with feedstock integration from chlorine; and (2) Epoxy/Building Products — windows, doors, pipes, fittings, trim, and siding sold to residential and commercial construction end markets. The building products segment (~40% of EBITDA at normalized conditions) carries a higher multiple than the commodity segment and provides through-cycle earnings support. WLK’s chlor-alkali integration gives it a differentiated cost position in PVC versus standalone resin producers.1
Thesis
- Near fair value; limited upside to PO. At 119 BofA PO. Excess market cap vs. excess EBITDA implies -1.0 quarters — i.e., BofA sees the current price as not pricing in overearning, making WLK the most fairly valued of the three names.1
- Building products offsets commodity weakness. The buildings segment will see a trough in commodity profits in 2027 as petchem pricing normalizes, but building products EBITDA continues growing, providing an earnings offset unavailable to DOW or LYB.1
- Blended valuation supports higher multiple. BofA applies an 8x FY26 EV/EBITDA (down from prior 10x), decomposed as 6x on the commodity business and 11x on building products — reflecting the earnings quality differential between segments.1
- Chlor-alkali/PVC exposure adds complexity. WLK’s vinyls chain benefits from both the Iran-driven ethylene/PE tailwind and any chlor-alkali spread improvement. However, absent a meaningful upturn in PVC/chlor-alkali pricing from current levels, the commodity segment faces the same post-conflict normalization headwinds as peers.1
- FY26 is not the run rate; 2027–2028 are normalized reference. FY26 EBITDA of 2,032mn in FY27 as commodity pricing fades. The PO reflects normalized earnings, not the peak.1
Risks
- Downside: No meaningful upturn in PVC/chlor-alkali prices and margins from current levels; faster-than-expected capacity expansion in chlor-alkali or PVC; deeper trough in polyethylene margins; broader macro weakness, especially in emerging markets weighing on vinyl demand.1
- Upside: Continued share gains in building products; inflection in chlor-alkali or polyethylene pricing and margins above BofA’s normalized assumptions; improving housing/construction macro; more favorable capacity rationalization in the industry.1
Recent catalysts
- 2026-04-06 — BofA downgrades WLK to Neutral from Buy; raises PO to 115; raises FY26 EBITDA to 386mn (+8%). Move to Neutral reflects strong YTD appreciation and limited further upside to revised PO; building products segment cited as the key differentiator vs. DOW/LYB.1
Second-order reads
- 2026-04-06 — BofA US Chemicals note — PVC and chlor-alkali pricing included in BofA’s +35cpp PE inflation assumption for US markets. Implication for WLK: near-term PVC margin tailwind likely, but building products segment provides the through-cycle differentiation that keeps WLK closer to fair value than peers.1
Valuation & positioning
| Metric | Value |
|---|---|
| Price (2026-04-05) | $117.00 |
| BofA Price Objective | $119 |
| Rating | Neutral |
| BofA valuation basis | 8.0x FY26E EV/EBITDA (6x commodity + 11x building products) |
| FY26E EBITDA | $2,322mn |
| FY27E EBITDA | $2,032mn |
| FY28E EBITDA | $2,269mn |
| FY26E EPS | $5.85 |
| FY27E EPS | $3.71 |
| FY28E EPS | $5.27 |
| Mkt cap | ~$15,016mn |
| Excess mkt cap / excess EBITDA | -1.0 quarters |
| Implied overearning duration | ~-0.2 years (at fair value) |
The 8x multiple is a premium to DOW (6.5x) and LYB (6.0x), justified by the building products segment’s higher earnings quality and lower cyclicality. BofA notes the 8x also implies ~6.0x on commodity EBITDA — consistent with peers — and ~11x on the building products EBITDA.1